Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11515753rdf:typepubmed:Citationlld:pubmed
pubmed-article:11515753lifeskim:mentionsumls-concept:C0699726lld:lifeskim
pubmed-article:11515753lifeskim:mentionsumls-concept:C0021368lld:lifeskim
pubmed-article:11515753lifeskim:mentionsumls-concept:C0007806lld:lifeskim
pubmed-article:11515753lifeskim:mentionsumls-concept:C0005854lld:lifeskim
pubmed-article:11515753lifeskim:mentionsumls-concept:C0277785lld:lifeskim
pubmed-article:11515753lifeskim:mentionsumls-concept:C0011164lld:lifeskim
pubmed-article:11515753lifeskim:mentionsumls-concept:C0678594lld:lifeskim
pubmed-article:11515753lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:11515753lifeskim:mentionsumls-concept:C0205420lld:lifeskim
pubmed-article:11515753pubmed:issue7lld:pubmed
pubmed-article:11515753pubmed:dateCreated2001-8-22lld:pubmed
pubmed-article:11515753pubmed:abstractTextCerebral dysfunction without corresponding structural pathology has been reported in brain imaging studies of violent offenders. Biochemical markers in the CSF reflect various types of CNS pathology, such as blood-brain barrier dysfunction (CSF/S albumin ratio), infectious or inflammatory processes (IgG and IgM indices), neuronal or axonal degeneration (CSF-tau protein) and synaptic de- or regeneration (CSF-growth associated protein-43 (GAP-43)). We compared these CSF markers in 19 non-psychotic perpetrators of severe violent crimes undergoing pretrial forensic psychiatric investigation and 19 age- and sex-matched controls. Index subjects had significantly higher albumin ratios (p = 0.002), indicating abnormal vascular permeability as part of the complex CNS dysfunction previously reported in violent offenders. Axis I disorders, including substance abuse or current medication, did not explain this finding. Since Ig-indices, CSF-tau protein or CSF-GAP-43 were not increased, there was no support for inflammation or neuronal/synaptic degeneration as etiological factors to CNS dysfunction in this category of subjects.lld:pubmed
pubmed-article:11515753pubmed:languageenglld:pubmed
pubmed-article:11515753pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11515753pubmed:citationSubsetIMlld:pubmed
pubmed-article:11515753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11515753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11515753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11515753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11515753pubmed:statusMEDLINElld:pubmed
pubmed-article:11515753pubmed:issn0300-9564lld:pubmed
pubmed-article:11515753pubmed:authorpubmed-author:ForsmanAAlld:pubmed
pubmed-article:11515753pubmed:authorpubmed-author:BlennowKKlld:pubmed
pubmed-article:11515753pubmed:authorpubmed-author:ManhemAAlld:pubmed
pubmed-article:11515753pubmed:authorpubmed-author:SoderstromHHlld:pubmed
pubmed-article:11515753pubmed:issnTypePrintlld:pubmed
pubmed-article:11515753pubmed:volume108lld:pubmed
pubmed-article:11515753pubmed:ownerNLMlld:pubmed
pubmed-article:11515753pubmed:authorsCompleteYlld:pubmed
pubmed-article:11515753pubmed:pagination879-86lld:pubmed
pubmed-article:11515753pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11515753pubmed:meshHeadingpubmed-meshheading:11515753...lld:pubmed
pubmed-article:11515753pubmed:meshHeadingpubmed-meshheading:11515753...lld:pubmed
pubmed-article:11515753pubmed:meshHeadingpubmed-meshheading:11515753...lld:pubmed
pubmed-article:11515753pubmed:meshHeadingpubmed-meshheading:11515753...lld:pubmed
pubmed-article:11515753pubmed:meshHeadingpubmed-meshheading:11515753...lld:pubmed
pubmed-article:11515753pubmed:meshHeadingpubmed-meshheading:11515753...lld:pubmed
pubmed-article:11515753pubmed:meshHeadingpubmed-meshheading:11515753...lld:pubmed
pubmed-article:11515753pubmed:meshHeadingpubmed-meshheading:11515753...lld:pubmed
pubmed-article:11515753pubmed:meshHeadingpubmed-meshheading:11515753...lld:pubmed
pubmed-article:11515753pubmed:meshHeadingpubmed-meshheading:11515753...lld:pubmed
pubmed-article:11515753pubmed:meshHeadingpubmed-meshheading:11515753...lld:pubmed
pubmed-article:11515753pubmed:meshHeadingpubmed-meshheading:11515753...lld:pubmed
pubmed-article:11515753pubmed:meshHeadingpubmed-meshheading:11515753...lld:pubmed
pubmed-article:11515753pubmed:meshHeadingpubmed-meshheading:11515753...lld:pubmed
pubmed-article:11515753pubmed:year2001lld:pubmed
pubmed-article:11515753pubmed:articleTitleCSF studies in violent offenders. II. Blood-brain barrier dysfunction without concurrent inflammation or structure degeneration.lld:pubmed
pubmed-article:11515753pubmed:affiliationDepartment of Psychiatry, Institute of Clinical Neuroscience, Göteborg University, Sweden. henrik.soderstrom@rmv.selld:pubmed
pubmed-article:11515753pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11515753pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:11515753pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed